Explore the benefits and considerations of adjuvant immunotherapy in the treatment of resectable non-small cell lung cancer (NSCLC). Review the latest clinical trials, including IMpower 010 and Checkmate 816, and learn about the potential role of neoadjuvant therapy.

11 views • 28 slides

Cancer care in India is undergoing a paradigm shift with the introduction of a new immunotherapy treatment: Dostarlimab. This potent formulation (7.5 mg\/5 ml) promises to change the treatment paradigm for oncologists as well as patients fighting cancer. Dostarlimab 7.5 mg\/5 ml is a revolutionary i

5 views • 7 slides

The Global Cancer Immunotherapy Market was valued at $39.86 billion in 2017 and is anticipated to reach $170.70 billion by 2028 during the forecast period of 2017-2028 and still the market is showing an increase in the ROI in the later years as well.

0 views • 3 slides

This trial aims to compare the efficacy and safety of molecularly-guided therapy or cancer immunotherapy based on genomic profiling with platinum-based chemotherapy in patients with cancer of unknown primary site. The study design includes multiple treatment regimens guided by genomic profiles, with

4 views • 9 slides

The history and advancements in cancer immunotherapy are highlighted, from early observations in the 1890s to the development of modern immunotherapies in the 2000s. Concepts such as immunosurveillance theory and the role of T cells in recognizing tumor-associated antigens are discussed, leading to

0 views • 22 slides

Enfortumab vedotin 20\/30 mg is an innovative treatment for advanced urothelial carcinoma. Targeting the Nectin-4 protein, it delivers a cytotoxic agent directly to cancer cells, reducing toxicity to healthy tissues. Available in India, Enfortumab vedotin 20\/30 mg in India has shown improved surviv

0 views • 10 slides

Veterinary oncology, led by Prof. David Killick, delves into the realm of spontaneous cancers in dogs, cats, and horses, mirroring the cancer evolution in humans. The field covers diagnosis through cytology and imaging to treatments like surgery, radiation, and emerging immunotherapy. University vet

0 views • 11 slides

Recent clinical trials such as TOPAZ-1, KEYNOTE-966, ClarIDHy, and FIGHT-202 have shown promising results in the treatment of cholangiocarcinoma. Trials with immunotherapy and targeted therapy have demonstrated improved overall survival rates, progression-free survival, and objective response rates

0 views • 6 slides

Explore the potential treatments for a 83-year-old male diagnosed with Stage III rectal cancer, including surgery, radiation therapy, chemotherapy, and immunotherapy. Learn about neoadjuvant and adjuvant therapies, complete response definitions, surgical techniques like total mesorectal excision (TM

0 views • 32 slides

A multi-cohort phase 2 study presented at ESMO 2020 evaluated the combination of durvalumab and tremelimumab in patients with advanced neuroendocrine neoplasms. The DUNE trial assessed the efficacy of this immunotherapy approach in various neuroendocrine tumor types, emphasizing the potential benefi

0 views • 17 slides

Blinatumomab 35 mcg Injection in India is a breakthrough immunotherapy used primarily to treat relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). This guide covers its mechanism, benefits, dosage, and availability in India. D

0 views • 11 slides

Explore the latest advancements in immunotherapy for managing bladder and renal cancer, including mechanisms of action, indications, adverse effects, and available treatment regimes. Learn about immune checkpoint inhibitors, differentiating immunotherapy from chemotherapy, indications for use across

0 views • 19 slides